FI3947384T3 - Isokromeenijohdannaisia fosfoinositidi-3-kinaasien estäjinä - Google Patents
Isokromeenijohdannaisia fosfoinositidi-3-kinaasien estäjinä Download PDFInfo
- Publication number
- FI3947384T3 FI3947384T3 FIEP20711985.0T FI20711985T FI3947384T3 FI 3947384 T3 FI3947384 T3 FI 3947384T3 FI 20711985 T FI20711985 T FI 20711985T FI 3947384 T3 FI3947384 T3 FI 3947384T3
- Authority
- FI
- Finland
- Prior art keywords
- methyl
- isochromen
- hydroxypyridin
- pyrazolo
- pyrimidin
- Prior art date
Links
- 108091007960 PI3Ks Proteins 0.000 title claims 4
- 102000003993 Phosphatidylinositol 3-kinases Human genes 0.000 title 1
- 108090000430 Phosphatidylinositol 3-kinases Proteins 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- 150000008372 isochromenes Chemical class 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims 16
- 206010011224 Cough Diseases 0.000 claims 9
- 125000000217 alkyl group Chemical group 0.000 claims 9
- 239000008194 pharmaceutical composition Substances 0.000 claims 9
- 150000003839 salts Chemical class 0.000 claims 7
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 6
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 5
- 102000010400 1-phosphatidylinositol-3-kinase activity proteins Human genes 0.000 claims 3
- 208000006673 asthma Diseases 0.000 claims 3
- 229910052799 carbon Inorganic materials 0.000 claims 3
- -1 from NH Chemical group 0.000 claims 3
- 239000000546 pharmaceutical excipient Substances 0.000 claims 3
- 239000000843 powder Substances 0.000 claims 3
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims 2
- 229940080296 2-naphthalenesulfonate Drugs 0.000 claims 2
- 125000002373 5 membered heterocyclic group Chemical group 0.000 claims 2
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims 2
- 201000009794 Idiopathic Pulmonary Fibrosis Diseases 0.000 claims 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 claims 2
- 150000001721 carbon Chemical group 0.000 claims 2
- 208000013116 chronic cough Diseases 0.000 claims 2
- 239000011362 coarse particle Substances 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 230000007247 enzymatic mechanism Effects 0.000 claims 2
- 208000021302 gastroesophageal reflux disease Diseases 0.000 claims 2
- 208000036971 interstitial lung disease 2 Diseases 0.000 claims 2
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 claims 2
- 239000000203 mixture Substances 0.000 claims 2
- KVBGVZZKJNLNJU-UHFFFAOYSA-M naphthalene-2-sulfonate Chemical compound C1=CC=CC2=CC(S(=O)(=O)[O-])=CC=C21 KVBGVZZKJNLNJU-UHFFFAOYSA-M 0.000 claims 2
- 229910052757 nitrogen Inorganic materials 0.000 claims 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 claims 2
- ODIGIKRIUKFKHP-UHFFFAOYSA-N (n-propan-2-yloxycarbonylanilino) acetate Chemical compound CC(C)OC(=O)N(OC(C)=O)C1=CC=CC=C1 ODIGIKRIUKFKHP-UHFFFAOYSA-N 0.000 claims 1
- 125000004195 4-methylpiperazin-1-yl group Chemical group [H]C([H])([H])N1C([H])([H])C([H])([H])N(*)C([H])([H])C1([H])[H] 0.000 claims 1
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 claims 1
- 206010006458 Bronchitis chronic Diseases 0.000 claims 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 1
- 208000029523 Interstitial Lung disease Diseases 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- XDCNONAJWUTNCH-UHFFFAOYSA-N NC1=C2C(=NC=N1)N(N=C2C=1C=NC=C(C=1)O)C(C)C=1OC(C2=CC=CC=C2C=1C1=CC(=CC=C1)C(C)N(C)C)=O Chemical compound NC1=C2C(=NC=N1)N(N=C2C=1C=NC=C(C=1)O)C(C)C=1OC(C2=CC=CC=C2C=1C1=CC(=CC=C1)C(C)N(C)C)=O XDCNONAJWUTNCH-UHFFFAOYSA-N 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 208000036142 Viral infection Diseases 0.000 claims 1
- 241000700605 Viruses Species 0.000 claims 1
- 239000002253 acid Substances 0.000 claims 1
- 239000013543 active substance Substances 0.000 claims 1
- 239000000654 additive Substances 0.000 claims 1
- 230000000996 additive effect Effects 0.000 claims 1
- 239000008135 aqueous vehicle Substances 0.000 claims 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 claims 1
- 206010006451 bronchitis Diseases 0.000 claims 1
- 208000007451 chronic bronchitis Diseases 0.000 claims 1
- 201000004897 cough variant asthma Diseases 0.000 claims 1
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- ZZUFCTLCJUWOSV-UHFFFAOYSA-N furosemide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(C(O)=O)=C1NCC1=CC=CO1 ZZUFCTLCJUWOSV-UHFFFAOYSA-N 0.000 claims 1
- 125000001188 haloalkyl group Chemical group 0.000 claims 1
- 229910052736 halogen Inorganic materials 0.000 claims 1
- 150000002367 halogens Chemical class 0.000 claims 1
- 125000005842 heteroatom Chemical group 0.000 claims 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 1
- 125000002768 hydroxyalkyl group Chemical group 0.000 claims 1
- SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical compound OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 claims 1
- 230000001050 lubricating effect Effects 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 210000003097 mucus Anatomy 0.000 claims 1
- DXASQZJWWGZNSF-UHFFFAOYSA-N n,n-dimethylmethanamine;sulfur trioxide Chemical group CN(C)C.O=S(=O)=O DXASQZJWWGZNSF-UHFFFAOYSA-N 0.000 claims 1
- 239000006199 nebulizer Substances 0.000 claims 1
- 125000004430 oxygen atom Chemical group O* 0.000 claims 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 1
- 210000002345 respiratory system Anatomy 0.000 claims 1
- 208000023504 respiratory system disease Diseases 0.000 claims 1
- YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 claims 1
- 229960001860 salicylate Drugs 0.000 claims 1
- 229910052717 sulfur Inorganic materials 0.000 claims 1
- 125000004434 sulfur atom Chemical group 0.000 claims 1
- 208000011580 syndromic disease Diseases 0.000 claims 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 claims 1
- 230000009385 viral infection Effects 0.000 claims 1
- 229950000339 xinafoate Drugs 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/10—Expectorants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/14—Antitussive agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pulmonology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Otolaryngology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP19167245 | 2019-04-04 | ||
| PCT/EP2020/058168 WO2020200918A1 (en) | 2019-04-04 | 2020-03-24 | Isochromene derivatives as phosphoinositide 3-kinases inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| FI3947384T3 true FI3947384T3 (fi) | 2024-01-30 |
Family
ID=66092138
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FIEP20711985.0T FI3947384T3 (fi) | 2019-04-04 | 2020-03-24 | Isokromeenijohdannaisia fosfoinositidi-3-kinaasien estäjinä |
Country Status (26)
| Country | Link |
|---|---|
| US (1) | US12527797B2 (enExample) |
| EP (1) | EP3947384B1 (enExample) |
| JP (1) | JP2022526973A (enExample) |
| KR (1) | KR20210149077A (enExample) |
| CN (1) | CN113874376A (enExample) |
| AR (1) | AR118588A1 (enExample) |
| AU (1) | AU2020252904A1 (enExample) |
| BR (1) | BR112021019589A2 (enExample) |
| CA (1) | CA3135309A1 (enExample) |
| DK (1) | DK3947384T3 (enExample) |
| ES (1) | ES2970530T3 (enExample) |
| FI (1) | FI3947384T3 (enExample) |
| HR (1) | HRP20240130T1 (enExample) |
| HU (1) | HUE065052T2 (enExample) |
| IL (1) | IL286937A (enExample) |
| MA (1) | MA55479A (enExample) |
| MX (1) | MX2021011979A (enExample) |
| MY (1) | MY206575A (enExample) |
| PH (1) | PH12021552402A1 (enExample) |
| PL (1) | PL3947384T3 (enExample) |
| PT (1) | PT3947384T (enExample) |
| SG (1) | SG11202110801XA (enExample) |
| SI (1) | SI3947384T1 (enExample) |
| TW (1) | TW202102504A (enExample) |
| WO (1) | WO2020200918A1 (enExample) |
| ZA (1) | ZA202107710B (enExample) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2024180207A1 (en) | 2023-03-02 | 2024-09-06 | Chiesi Farmaceutici S.P.A. | Pyridazinyl amino derivatives as alk5 inhibitors |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9501841D0 (en) | 1995-01-31 | 1995-03-22 | Co Ordinated Drug Dev | Improvements in and relating to carrier particles for use in dry powder inhalers |
| PT1158958E (pt) | 1999-03-05 | 2007-08-13 | Chiesi Farma Spa | ''composições farmacêuticas em pó, melhoradas, para inalação'' |
| LT2496567T (lt) | 2009-11-05 | 2017-11-27 | Rhizen Pharmaceuticals S.A. | Nauji benzopirano kinazės moduliatoriai |
| TWI672297B (zh) | 2013-12-18 | 2019-09-21 | 義大利商吉斯藥品公司 | 作為磷脂肌醇－３－激酶抑制劑之異唏衍生物 |
| ES2750791T3 (es) | 2014-06-17 | 2020-03-27 | Chiesi Farm Spa | Derivados de indolizina como inhibidores de fosfoinositido 3-quinasas |
| US9745308B2 (en) | 2014-09-12 | 2017-08-29 | Chiesi Farmaceutici S.P.A. | Pyridazinone derivatives as phoshoinositide 3-kinases inhibitors |
| US9968604B2 (en) | 2015-04-16 | 2018-05-15 | Chiesi Farmaceutici S.P.A. | Chromene derivatives as phoshoinositide 3-kinases inhibitors |
| WO2017134053A1 (en) | 2016-02-04 | 2017-08-10 | Chiesi Farmaceutici S.P.A. | Pyrazole derivatives as phosphoinositide 3-kinases inhibitors |
-
2020
- 2020-03-24 EP EP20711985.0A patent/EP3947384B1/en active Active
- 2020-03-24 MA MA055479A patent/MA55479A/fr unknown
- 2020-03-24 US US17/600,676 patent/US12527797B2/en active Active
- 2020-03-24 FI FIEP20711985.0T patent/FI3947384T3/fi active
- 2020-03-24 MX MX2021011979A patent/MX2021011979A/es unknown
- 2020-03-24 DK DK20711985.0T patent/DK3947384T3/da active
- 2020-03-24 HR HRP20240130TT patent/HRP20240130T1/hr unknown
- 2020-03-24 MY MYPI2021005864A patent/MY206575A/en unknown
- 2020-03-24 HU HUE20711985A patent/HUE065052T2/hu unknown
- 2020-03-24 CA CA3135309A patent/CA3135309A1/en active Pending
- 2020-03-24 WO PCT/EP2020/058168 patent/WO2020200918A1/en not_active Ceased
- 2020-03-24 PT PT207119850T patent/PT3947384T/pt unknown
- 2020-03-24 JP JP2021558911A patent/JP2022526973A/ja active Pending
- 2020-03-24 ES ES20711985T patent/ES2970530T3/es active Active
- 2020-03-24 PH PH1/2021/552402A patent/PH12021552402A1/en unknown
- 2020-03-24 SI SI202030355T patent/SI3947384T1/sl unknown
- 2020-03-24 PL PL20711985.0T patent/PL3947384T3/pl unknown
- 2020-03-24 SG SG11202110801XA patent/SG11202110801XA/en unknown
- 2020-03-24 KR KR1020217033595A patent/KR20210149077A/ko not_active Withdrawn
- 2020-03-24 BR BR112021019589A patent/BR112021019589A2/pt not_active Application Discontinuation
- 2020-03-24 AU AU2020252904A patent/AU2020252904A1/en not_active Abandoned
- 2020-03-24 CN CN202080034539.2A patent/CN113874376A/zh active Pending
- 2020-03-27 TW TW109110464A patent/TW202102504A/zh unknown
- 2020-04-03 AR ARP200100946A patent/AR118588A1/es not_active Application Discontinuation
-
2021
- 2021-10-03 IL IL286937A patent/IL286937A/en unknown
- 2021-10-12 ZA ZA2021/07710A patent/ZA202107710B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| ES2970530T3 (es) | 2024-05-29 |
| CA3135309A1 (en) | 2020-10-08 |
| MX2021011979A (es) | 2021-11-03 |
| HRP20240130T1 (hr) | 2024-04-12 |
| AU2020252904A1 (en) | 2021-11-18 |
| SG11202110801XA (en) | 2021-10-28 |
| AR118588A1 (es) | 2021-10-20 |
| ZA202107710B (en) | 2025-03-26 |
| JP2022526973A (ja) | 2022-05-27 |
| HUE065052T2 (hu) | 2024-04-28 |
| PH12021552402A1 (en) | 2022-06-20 |
| DK3947384T3 (da) | 2024-01-08 |
| EP3947384A1 (en) | 2022-02-09 |
| MY206575A (en) | 2024-12-24 |
| CN113874376A (zh) | 2021-12-31 |
| EP3947384B1 (en) | 2023-11-01 |
| WO2020200918A1 (en) | 2020-10-08 |
| US20220175784A1 (en) | 2022-06-09 |
| US12527797B2 (en) | 2026-01-20 |
| BR112021019589A2 (pt) | 2021-12-07 |
| MA55479A (fr) | 2022-02-09 |
| PT3947384T (pt) | 2024-01-29 |
| IL286937A (en) | 2021-10-31 |
| SI3947384T1 (sl) | 2024-03-29 |
| KR20210149077A (ko) | 2021-12-08 |
| PL3947384T3 (pl) | 2024-03-25 |
| TW202102504A (zh) | 2021-01-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2014225761B2 (en) | Compounds for treatment of cancer | |
| JP6021805B2 (ja) | 腫瘍治療剤 | |
| JP2014526500A5 (enExample) | ||
| US20170157134A1 (en) | Combination therapy | |
| RU2015121037A (ru) | Производные фенилэтилпиридина в качестве ингибиторов pde-4 | |
| CN103857392A (zh) | 用于治疗增生性疾病的2-甲酰胺环氨基尿素衍生物与Hsp90抑制剂的组合 | |
| JP2013510123A5 (enExample) | ||
| RU2015121043A (ru) | Производные фенилэтилпиридина в качестве ингибиторов PDE-4 | |
| JP2012515787A5 (enExample) | ||
| RU2012153164A (ru) | Производные мочевины и их терапевтическое применение при лечении, среди прочего, заболеваний дыхательного пути | |
| RU2016134751A (ru) | Соединения | |
| JP2016513661A5 (enExample) | ||
| US20230059381A1 (en) | Prophylactic or therapeutic agent for neuropathic pain associated with guillain-barre syndrome | |
| JP2021535112A5 (enExample) | ||
| JP2016503797A5 (enExample) | ||
| JP2014502979A5 (enExample) | ||
| AU2019270089B2 (en) | Compounds for treatment of triple negative breast cancer and ovarian cancer | |
| JP2019517564A5 (enExample) | ||
| JP2016505637A5 (enExample) | ||
| RU2015121046A (ru) | Соединения, обладающие активностью антагонистов мускариновых рецепторов и агонистов бета-2-адренергических рецепторов | |
| JP2014505107A5 (enExample) | ||
| RU2015117647A (ru) | Новые производные пиразола | |
| RU2014100744A (ru) | Лечение респираторных нарушений с помощью trpa1 антагонистов | |
| JP2016525104A5 (enExample) | ||
| RU2016121854A (ru) | Производные гетероарила |